---
schema_version: "secwatch.filing_event.v1"
accession: "0000012208-22-000005"
form_type: "8-K"
ticker: "BIO"
cik: "0000012208"
company_name: "BIO-RAD LABORATORIES, INC."
filed_at: "2022-02-10T23:59:59+00:00"
generated_at: "2026-06-27T09:04:05.037571+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Bio-Rad Q4 revenue down 7.2% to $733M; GAAP loss $52.59/sh, non-GAAP EPS $3.21; 2022 outlook 1-2% growth

## Summary
- Q4 2021 sales $732.8M (-7.2% YoY); Life Science sales down 23.8% on lower COVID-related qPCR demand.
- GAAP net loss $1,573.7M ($52.59 loss per diluted share) vs net income $839.1M in Q4 2020, impacted by Sartorius AG fair value changes.
- Non-GAAP net income $97.0M ($3.21 per share) vs $121.0M ($4.01) in Q4 2020.
- Full year 2021 sales $2,922.5M (+14.8% reported); core revenue ex-COVID up 17.0% currency-neutral.
- 2022 guidance: non-GAAP currency-neutral revenue growth 1-2%, non-GAAP operating margin ~19.0%.

## SEC filing metadata
- accession: 0000012208-22-000005
- form_type: 8-K
- ticker: BIO
- cik: 0000012208
- company_name: BIO-RAD LABORATORIES, INC.
- filed_at: 2022-02-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/12208/000001220822000005/0000012208-22-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/12208/000001220822000005/bio-20220210.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000012208-22-000005
- JSON: https://secwatch.observer/filing/0000012208-22-000005.json
- Plain text: https://secwatch.observer/filing/0000012208-22-000005.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.